Topics

Companies Related to "Extremely antibiotic resistant superbugs spreading hospitals across Europe" [Most Relevant Company Matches] RSS

08:19 EST 22nd January 2020 | BioPortfolio

Here are the most relevant search results for "Extremely antibiotic resistant superbugs spreading hospitals across Europe" found in our extensive corporate database of over 50,000 company records.

Showing "Extremely antibiotic resistant superbugs spreading hospitals across Europe" Companies 1–25 of 3,400+

Relevant

Pharmaceutica Limited

Pharmaceutica Limited is a privately owned pharmaceutical company founded in March 2003, to discover and develop a new generation of anti-infective drug technologies that combat the increasing problem caused by the rapid evolution of resistance by pathogenic organisms. The company is targeting both human and veterinary applications for its technologies.The initial focus is to find a solution to th...


AdvanDx, Inc

AdvanDx announces that at the recent American Society for Microbiology (ASM) meeting in Orlando, Florida, EVIGENE™ kits for detecting specific antibiotic resistance, virulence, and toxicity markers such as methicillin-resistance, vancomycin-resistance, PVL and TSST-1 in Staphylococcus aureus and enterococci, were launched for research use only in the United States. EVIGENE was officially launch...

Phage Biotech Ltd.

Phage-Biotech Ltd. was incorporated in March 2000, as a new player in the emerging field of Phage Therapy. The Company’s mission is to develop proprietary Phage-based anti-infective therapeutics to combat the increasing number of antibiotic-resistant infections worldwide. The Company has two short-term strategic objectives:To identify and formulate proprietary topical Phage preparations from dis...


Special Phage Services

Few inventions in science and medicine have had such a profound effect on human health as the discovery and subsequent development of antibiotics. Following their introduction during World War II many dreaded infectious diseases such as diphtheria, pneumonia, syphilis, and tuberculosis disappeared almost overnight. However all is not well with the antibiotics story. The bacterial pathogens are f...

Microbiotix, Inc.

Microbiotix, Inc. is a privately held, product-focused biopharmaceutical company engaged in the research and development of novel small molecule, anti-infective drugs that address commercially significant medical markets. The company currently has four novel compound series in research and development. Microbiotix currently has in development MBX 500, the first antibiotic that targets the DNA po...

Helperby Therapeutics Ltd Helperby Therapeutics

Helperby is a biopharmaceutical company dedicated to developing the next generation of lifesaving antibiotics. Helperby’s unique antibiotic technology outsmarts highly resistant bacteria by combining new resistance breakers with old antibiotics to create a whole new generation of therapies. The Company was spun out of St George’s University Hospi...

Lakewood-Amedex Inc.

Lakewood-Amedex is a privately held development-stage biopharmaceutical company with a broad patent portfolio of inventions, including, 24 granted and/or issued patents and 45 patent applications covering its proprietary NuBiotics family of anti-microbial products, proven to be effective against a wide range of bacteria, encompassing antibiotic resistant strains including methicillin-resistant Sta...

Lakewood-Amedex, Inc.

Lakewood-Amedex is a privately held development-stage biopharmaceutical company with a broad patent portfolio of inventions, including, 24 granted and/or issued patents and 45 patent applications covering its proprietary NuBiotics family of anti-microbial products, proven to be effective against a wide range of bacteria, encompassing antibiotic resistant strains including methicillin-resistant Sta...

Lysando AG

Lysando AG is a technology leader in the area of antimicrobial proteins. Since its foundation in 2009, the privately financed research company has done research on artificial designer proteins with a team of scientists in the town of Regensburg. Artilysin®s represent a revolutionary breakthrough in the battle against multi-resistant bacteria. With this ...

Arsanis Inc

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The company’s major focus is on life threatening infections that are caused by antibiotic resistant pathogens, occur in immune compromised patients or are associated with ...

Arsanis, Inc

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that: are caused by antibiotic resistant pathogens; occur in immune compromised patients; or are associated wit...

Arsanis Biosciences GmbH

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that are caused by antibiotic resistant pathogens, occur in immune compromised patients or are associated with ...

Arsanis, Inc.

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that: are caused by antibiotic resistant pathogens; occur in immune compromised patients; or are associated wit...

Destiny Pharma Ltd

Destiny Pharma is a UK based anti-infectives pharmaceutical company founded, in 1997, by pharma industry executives. The company has developed and patented a portfolio of novel drugs that have a completely different mode of action from conventional antibiotics. These compounds (codenamed XF Drugs) have been shown to work in such a way that minimizes the development of bacterial resistance to repea...

Fero Industries, Inc.

Fero Industries, Inc. is a publicly traded holding company (OTC BB: FROI.OB). Fero’s mission is to acquire healthcare related companies, products, and technologies that have large market potential, improve the quality of care, or have unmet needs. Fero’s initial focus is on diabetes. The Company has acquired the intellectual property and other exclusive world-wide rights related to...

Procarta Biosystems

Procarta Biosystems is developing a new class of DNA-based therapeuticals, snare™ antibacterials, capable of combating drug-resistant bacterial infections. snare™ antibacterials act on novel genomic targets by capturing key regulatory proteins to block essential bacterial genes and defeat infection. Procarta is creating an extensive pipeline to tackle some of the most challenging b...

UTILITY therapeutics Limited

UTILITY therapeutics is focused on developing and commercialising antibiotics in the US, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections. The World Health Organisation has stated that antibiotic resistance is one of the biggest threats to global health, food security, and development...

Mpex Pharmaceuticals

Mpex Pharmaceuticals is focused on the discovery and development of new anti-bacterial drugs that meet the growing clinical need created by multi-drug resistant bacterial pathogens. It is well documented that antibiotic resistance is a growing, serious problem in both the hospital and community setting. Mpex's approach is to improve the activity of existing antibiotics by utilizing methods and pot...

UTILITY therapeutics Ltd

UTILITY is focused on developing and commercialising antibiotics in the US, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections. The World Health Organisation has stated that antibiotic resistance is one of the biggest threats to global health, food security, and development today.

NovaDigm Therapeutics

NovaDigm is developing innovative vaccines to protect patients from fungal and bacterial infections, which can be life-threatening and drug resistant. The Company’s founding scientists from the LA BioMed Institute at Harbor-UCLA Medical Center are recognized leaders in the field of infectious disease and the emerging threat of “superbugs.” N...

MDG Medical Inc.

Based in Cleveland, Ohio, with its research and development subsidiary in Israel, MDG Medical develops technology and services that improve medical care and prevent medication errors in hospitals and other healthcare facilities. MDG’s flagship product is ServeRx®, a system that reduces human error in medication distribution and improves both the efficiency of medical staff and the manage...

Allecra Therapeutics GmbH

Allecra Therapeutics Allecra is a biopharmaceutical company established in 2013 focussed on the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra’s Mission Allecra’s mission is to contribute towards the global effort to combat antibiotic resistance by developing new treatments which overcome emerging resistance mechanisms thereby saving ...

AmpliPhi Biosciences Corporation

AmpliPhi Biosciences Corporation is a biotechnology company dedicated to the development of innovative anti-bacterial solutions to improve human health through the application of its proprietary bacteriophage platform. The Company’s lead product development programs are targeting gram negative bacterial infections that are often resistant to existing ...

Appili Therapeutics Inc.

Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501 is a taste-masked treatment for anaerobic infections, including C. difficile. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential ...

Ipsat Therapies Oy

Ipsat Therapies Ltd is a Finnish biotechnology company developing its proprietary IPSAT™ (“Intestinal Protection System in Antibiotic Treatment”) family of products for the prevention of hospital infections and antibiotic resistance


More From BioPortfolio on "Extremely antibiotic resistant superbugs spreading hospitals across Europe"

Quick Search

Corporate Database Quicklinks